Landos Biopharma has been granted a patent for compounds that target the NLRX1 pathway, which can be used to treat various conditions including inflammatory diseases, immune-mediated diseases, cancers, and infectious diseases. The compounds have a specific formula and structure. GlobalData’s report on Landos Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Landos Biopharma, peptide pharmacophores was a key innovation area identified from patents. Landos Biopharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Compound targeting nlrx1 pathway for treating various diseases
A recently granted patent (Publication Number: US11680045B2) discloses a compound and its use in treating various conditions in animals. The compound, referred to as "Z," is described as having an A ring, a B ring, a C ring, and a D ring, or a salt thereof. The patent claims cover different variations of the compound and its potential therapeutic applications.
According to the claims, the compound Z can have different substituents on the A ring, including hydroxy, halo, carboxyl, amino, alkyl, alkoxy, acyl, aryl, or any combination thereof. The compound can also have specific substitutions on the A ring, such as the absence of R5. Additionally, the claims describe variations where the A ring and the B ring have the same substituents and substitutions.
The patent also includes a method of treating various conditions in animals using the compound Z. The conditions mentioned in the claims include inflammatory, immune-mediated, or chronic gastrointestinal diseases, systemic immune-mediated diseases, cancer, and infectious diseases. The method involves administering an effective amount of the compound to the animal.
Overall, the granted patent provides protection for a compound (Z) and its potential therapeutic applications in animals. The compound can have different substituents and substitutions on its rings, allowing for variations in its chemical structure. The method of treatment described in the patent suggests that the compound may have potential in addressing a range of conditions, including inflammatory and immune-mediated diseases, cancer, and infectious diseases. However, it is important to note that the patent claims do not provide specific details about the compound's mechanism of action or clinical data supporting its efficacy.
To know more about GlobalData’s detailed insights on Landos Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
